• Теги
    • избранные теги
    • Компании1448
      • Показать ещё
      Разное381
      • Показать ещё
      Страны / Регионы304
      • Показать ещё
      Люди98
      • Показать ещё
      Международные организации18
      • Показать ещё
      Издания57
      • Показать ещё
      Формат34
      Показатели34
      • Показать ещё
Выбор редакции
01 марта, 15:52

Mylan's stock soars 7.5% premarket after Q4 results

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

28 февраля, 17:39

Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat

Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Zacks Consensus Estimate of a loss of $1.07 and the year-ago loss of $1.23.

28 февраля, 15:17

Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More

With the curtains almost down on the Q4 earnings season, we believe this quarter has turned out to be a good one with growth on track to be the highest in the last two years.

25 февраля, 00:15

Mylan (MYL) to Post Q4 Earnings: Will the Stock Disappoint?

Mylan N.V. (MYL) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.

22 февраля, 23:13

Momenta Tops Q4 Earnings, Shares Down on Warning Letter

Momenta's (MNTA) fourth quarter results beat estimates by a wide-margin. However, the issuance of a warning letter to manufacturer Pfizer for Glatopa was disappointing.

22 февраля, 03:42

Where Are the Best Buying Opportunities in Stocks Right Now?

With stocks hitting new record highs, you might think there???s nothing left to buy. But some of the biggest money managers beg to differ.

17 февраля, 23:34

Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

14 февраля, 16:20

Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance

Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.

09 февраля, 17:30

Zacks Market Edge Highlights: Health Care SPDR ETF, iShares NASDAQ Biotechnology ETF, Acadia, Aetna and Gilead

Zacks Market Edge Highlights: Health Care SPDR ETF, iShares NASDAQ Biotechnology ETF, Acadia, Aetna and Gilead

08 февраля, 03:47

Healthcare Stocks: The Buying Opportunity of the Year?

Tracey and Kevin discuss whether healthcare stocks are still the ???sure things??? they???ve been the last 10 years.

Выбор редакции
07 февраля, 16:15

Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO

Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.

Выбор редакции
04 февраля, 16:00

How Drug Companies Have Raised Prescription Prices

In this week’s chart, we’re looking at how drug companies have consistently raised prescription prices... and why that business model is under threat today.

01 февраля, 18:11

Momenta Says District of Delaware Invalidates Teva's MS Drug

Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .

Выбор редакции
31 января, 18:45

Mylan (MYL) Gets Favorable Verdict for Copaxone in the US

Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the company pertaining to claims related to Teva Pharmaceutical's (TEVA) Copaxone 40mg/mL.

Выбор редакции
31 января, 18:10

Company News for January 31, 2017

Companies in the News are: MYL,TPX,MFRM,RGLS,DGLY

Выбор редакции
Выбор редакции
30 января, 23:27

Mylan shares drop 2.0% after Bloomberg report says it's facing U.S. antitrust investigation over EpiPen

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Выбор редакции